Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...
Synlogic (NASDAQ:SYBX) initiated Synpheny-3, a global, Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU), a rare inherited disorder that causes an amino...
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific...
Profound Medical (NASDAQ:PROF; TSX:PRN) announced that, with sponsorship and support from multiple physician specialty societies, it has received from the American Medical Association (AMA) three new Current Procedural...
Ondine Biomedical (LON:OBI) appointed Simon Sinclair, M.D., Ph.D., as chief medical officer, as the company prepares to start a U.S. Phase 3 trial of its nasal photodisinfection technology. Dr. Sinclair has more than 20...
Vistagen (NASDAQ:VTGN) presented positive safety and exploratory efficacy data at the American Society for Clinical Psychopharmacology annual meeting in Miami from its large Phase 3 open-label study of fasedienol nasal...
Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given the “strong data that has...
Closely-held Glyscend Therapeutics reported that Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of its lead candidate, GLY-200, offers significant and clinically relevant reductions in...
BioLight (TASE:BOLT) signed a research collaboration agreement with Alexion, a rare disease unit of AstraZeneca, to explore a potentially ground-breaking technology that utilizes natural tears for the potential...
SVB Securities upgraded Elevation Oncology (NASDAQ:ELEV) to “outperform” from “market perform” and raised its price target to $8 from $5, following the abstract release for EO-3021 (Claudin 18.2) ahead of ASCO. “This is...
Profound Medical (NASDAQ:PROF; TSX:PRN) will unveil interim five-year follow-up data from its TACT (TULSA-PRO ablation clinical trial) pivotal study at a live webinar event it is hosting on June 6 at 6 pm ET. The...